Healthcare Industry Reports

Key Findings

• India's IVF market is growing at ~18% CAGR, with Tier 2 cities now accounting for 31% of new cycle volumes
• Average cost-per-cycle has declined 22% over 5 years, driven by organised chain expansion and insurance tie-ups
• Patient awareness remains the primary barrier in non-metro markets — not affordability

Key Findings

• Defining the decision — not just the topic — is the single most important step before commissioning research
• Sample design errors are the leading cause of unreliable findings in Indian healthcare studies
• Most clients underestimate the value of a research debrief versus a written report alone

Key Findings

• Over 80% of India's cataract surgical backlog sits in Tier 2, Tier 3, and rural markets — largely unserved by organised chains
• Paediatric eye care and low vision rehabilitation are the most underprovided sub-specialties nationally
• Rising screen time is driving a surge in myopia among urban under-18s — a largely unaddressed outpatient opportunity

Key Findings

• Break-even occupancy for a 2-OT surgical centre ranges from 58–72% depending on specialty mix and city tier
• Ophthalmology and orthopaedics deliver the highest revenue-per-OT-hour among elective surgical specialties
• Staff cost as a percentage of revenue is the single largest differentiator between profitable and loss-making centres

Key Findings

• 14 of the 22 cities have specialist-to-population ratios below 40% of the national average — a structural supply gap
• Outpatient volume growth in the identified cities is running at 2.1x the rate of the top 8 metros
• Diagnostic infrastructure is the most acute bottleneck — present in only 6 of the 22 cities at adequate scale

Key Findings

• Less than 4% of India's 140 million seniors currently access any form of organised senior care
• Willingness-to-pay for senior living is concentrated in a narrow urban affluent segment — far smaller than headline projections suggest
• Family-based care remains the dominant model; organised alternatives face deep cultural resistance outside metros

Key Findings

• Premium salon formats (ticket size ₹1,500+) are growing at 2.4x the rate of the overall organised salon market
• Female consumers aged 25–40 in Tier 1 and Tier 2 cities are the primary demand driver — underpenetrated by existing chains
• Experience quality and hygiene perception outrank price as selection criteria in the premium segment

Key Findings

• India registers 1.4 million new cancer cases annually — over 70% are diagnosed at Stage III or IV due to late detection
• Fewer than 200 dedicated cancer hospitals serve a population of 1.4 billion; Tier 2 and Tier 3 cities are critically underserved
• Radiation therapy infrastructure is the most acute bottleneck — only 1 linear accelerator per 1.5 million people nationally

Key Findings

• India's healthcare market exceeds US$ 400 billion in FY26 — the 5th largest globally
• Diagnostics and pharma are the two highest-margin sub-sectors — both growing at 12–15% CAGR
• Health insurance penetration remains below 40% — the single largest structural constraint on organised healthcare growth

Key Findings

• Standalone health insurers (SAHIs) have grown from ~30% to ~41% of non-life market share in five years
• Retail health insurance is growing at 20%+ annually — the profit engine of the sector
• 30–40 crore Indians in the "missing middle" carry no meaningful health insurance

Key Findings

• India's hospital market is US$ 110–130 billion in FY26, growing at 8–10% CAGR
• India has 1.5–1.6 beds per 1,000 population vs a global benchmark of ~3
• Leading chains report ARPOB of ₹45,000–70,000+ per day in metro tertiary facilities

Key Findings

• India's MedTech market is US$ 12–15 billion in FY26, growing at 12–15% CAGR
• India remains 70–80% import-dependent in value terms — a figure that has barely moved in a decade
• The most consistent returns accrue to distribution, service contracts, and reagent-annuity models

Key Findings

• India's pharma industry is US$ 55–65 billion in FY26 — split roughly evenly between domestic and exports
• India supplies ~20% of global generic drug volumes; exports run at US$ 27–30+ billion annually
• US generics — the core export engine — face mid-to-high single digit annual price erosion

Key Findings

• PE/VC deploy US$ 2–3 billion+ annually into Indian healthcare — ~US$ 500–600 million per quarter
• Hospitals and single-specialty chains absorb the largest share of capital
• Pharma services (CDMO/CRO) is the strongest thematic bid, driven by China+1 diversification

Key Findings

• Organised single-specialty grows at ~22% CAGR to 2030 — twice the pace of the overall provider market
• The segment nearly triples: ~US$ 4.4 billion (2025) → ~US$ 12.3 billion (2030), rising from ~8% to ~13% of the provider market
• US$ 1.4 billion+ of PE entered single-specialty formats in two years; IVF absorbed ~US$ 942 million — conviction and crowding in one number

Key Findings

• Generic semaglutide launched at ₹1,290/month — a 90% collapse from branded pricing of up to ₹16,400/month
• In the 12 months to Feb 2026, at pre-expiry branded prices, GLP-1 sales hit ₹1,446 Cr, up 178% YoY
• Structured-program clinic economics support an estimated 25–35% contribution margin — the drug itself is now the cheapest component of doing GLP-1 therapy properly